Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 191 to 200 of 552 total matches.
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
was based on the results of two 28-
day, double-masked trials in patients with dry eye
disease (ONSET-1 ...
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the US
for this indication. An oral formulation of varenicline
(Chantix, and generics) has been available for years
for smoking cessation.
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
drugs, including carbapenems.1 Polymyxins B and E (colistin) have been used as salvage therapy ...
The FDA has approved Xacduro (Innoviva), a
combination of the beta-lactam antibacterial
sulbactam and the beta-lactamase inhibitor
durlobactam, for IV treatment of adults with hospital-acquired
or ventilator-associated bacterial pneumonia
caused by susceptible isolates of Acinetobacter
baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90 doi:10.58347/tml.2023.1690c | Show Introduction Hide Introduction
Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019 (Issue 1579)
, and insomnia.
▶ A schedule IV controlled substance.
▶ A 30-day supply costs $660.00.
Table 1. Pharmacology ...
The FDA has approved solriamfetol (Sunosi – Jazz),
a dopamine and norepinephrine reuptake inhibitor
(DNRI), to improve wakefulness in adults with excessive
daytime sleepiness (EDS) associated with narcolepsy
or obstructive sleep apnea (OSA). Pitolisant (Wakix),
an H3-receptor antagonist/inverse agonist recently
approved by the FDA for treatment of excessive
daytime sleepiness in patients with narcolepsy, will be
reviewed in a future issue.
Cenobamate (Xcopri) for Focal Seizures
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
be tried as monotherapy before
considering use of two drugs concurrently.1 Despite
the availability ...
The FDA has approved cenobamate (Xcopri – SK Life
Science) for oral treatment of partial-onset (focal)
seizures in adults.
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
of apomorphine
(Apokyn) has been available for years for the same
indication in patients with advanced PD.1 ...
The FDA has approved a sublingual fi lm formulation
of the nonergot dopamine agonist apomorphine
(Kynmobi – Sunovion) for acute, intermittent treatment
of "off" episodes in patients with Parkinson's disease
(PD). A subcutaneous formulation of apomorphine
(Apokyn) has been available for years for the same
indication in patients with advanced PD.
Ofatumumab (Kesimpta) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
progressive MS, was the first.1 An IV
formulation of ofatumumab (Arzerra) has been
available for treatment ...
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has...
Topical Roflumilast (Zoryve) for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
.1
TOPICAL TREATMENT ― Topical corticosteroids are
generally used for initial treatment of mild ...
The FDA has approved a 0.3% cream formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of plaque
psoriasis in patients ≥12 years old. Roflumilast is
the first topical PDE4 inhibitor to be approved by the
FDA for this indication; crisaborole (Eucrisa), another
topical PDE4 inhibitor, is approved for treatment
of atopic dermatitis. Oral roflumilast (Daliresp)
is approved for treatment of chronic obstructive
pulmonary disease.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):10-2 doi:10.58347/tml.2023.1668b | Show Introduction Hide Introduction
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
into (or first
appearing in) adulthood or even old age.1,2
NONPHARMACOLOGIC THERAPY
Skin hydration (a daily ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Brexanolone (Zulresso) for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
for treatment of refractory PPD.1
PHARMACOLOGY — Brexanolone positively modulates
neuronal activation ...
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso – Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for this indication.
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
1. KJ Ivey. Anticholinergics: do they work ...
The FDA has approved adjunctive treatment with
Dartisla ODT (Edenbridge), a new orally disintegrating
tablet (ODT) formulation of the anticholinergic drug
glycopyrrolate, to reduce symptoms of a peptic ulcer.
Glycopyrrolate oral tablets (Robinul, Robinul Forte,
and generics) were approved for the same indication
in 1961.